Date Filed | Type | Description |
06/16/2023 |
4
| Shepard Jay (Director) has filed a Form 4 on Esperion Therapeutics, Inc.
Txns:
| Granted 5,150 shares
@ $0 Granted 21,000 options to buy
@ $1.37, valued at
$28.8k
|
|
05/16/2023 |
4
| Shepard Jay (Director) has filed a Form 4 on INOVIO PHARMACEUTICALS, INC.
Txns:
| Exercised 19,000 restricted stock units
@ $0 Granted 35,000 options
@ $0.77, valued at
$27k
Granted 26,000 restricted stock units
@ $0 |
|
01/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
06/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/27/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/18/2022 |
4
| Shepard Jay (Director) has filed a Form 4 on INOVIO PHARMACEUTICALS, INC.
Txns:
| Exercised 4,274 restricted stock units
@ $0 |
|
06/04/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/28/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/17/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
01/15/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/03/2020 |
4
| Shepard Jay (Director) has filed a Form 4 on IRONWOOD PHARMACEUTICALS INC
Txns:
| Granted 24,727 shares
@ $0 Granted 10,830 shares
@ $0 |
|
12/03/2020 |
3
| Shepard Jay (Director) has filed a Form 3 on IRONWOOD PHARMACEUTICALS INC |
05/29/2020 |
4
| Shepard Jay (Director) has filed a Form 4 on Esperion Therapeutics, Inc.
Txns:
| Granted 6,106 shares
@ $0 |
|
05/15/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/09/2020 |
4
| Shepard Jay (Former Director) has filed a Form 4 on Aravive, Inc.
Txns:
| Disposed/sold 9,291 shares
@ $0 |
|
01/16/2020 |
4
| Shepard Jay (Director) has filed a Form 4 on INOVIO PHARMACEUTICALS, INC.
Txns:
| Granted 12,821 restricted stock units
@ $0 Granted 20,000 options
@ $3.35, valued at
$67k
|
|
01/16/2020 |
3
| Shepard Jay (Director) has filed a Form 3 on INOVIO PHARMACEUTICALS, INC. |
01/09/2020 |
4
| Shepard Jay (Director) has filed a Form 4 on Aravive, Inc.
Txns:
| Granted 5,075 options
@ $13.77, valued at
$69.9k
|
|
12/26/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/08/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/31/2019 |
4
| Shepard Jay (Director) has filed a Form 4 on Esperion Therapeutics, Inc.
Txns:
| Granted 4,967 shares
@ $0 |
|
05/13/2019 |
4
| Shepard Jay (President and CEO) has filed a Form 4 on Aravive, Inc.
Txns:
| Sold 1,192 shares
@ $6.11, valued at
$7.3k
|
|
03/04/2019 |
4
| Shepard Jay (President and CEO) has filed a Form 4 on Aravive, Inc.
Txns:
| Granted 116,000 options
@ $5.83, valued at
$676.3k
|
|
02/05/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/26/2018 |
4
| Shepard Jay (President and CEO) has filed a Form 4 on Aravive, Inc.
Txns:
| Sold 3,484 shares
@ $3.224, valued at
$11.2k
|
|
12/19/2018 |
4
| Shepard Jay (President and CEO) has filed a Form 4 on Aravive, Inc.
Txns:
| Sold 11,247 shares
@ $3.962, valued at
$44.6k
|
|
05/29/2018 |
4
| Shepard Jay (Director) has filed a Form 4 on Esperion Therapeutics, Inc.
Txns:
| Granted 18,700 options to buy
@ $37.69, valued at
$704.8k
|
|
05/29/2018 |
3
| Shepard Jay (Director) has filed a Form 3 on Esperion Therapeutics, Inc. |
05/23/2018 |
4
| Shepard Jay (President and CEO) has filed a Form 4 on Versartis, Inc.
Txns:
| Sold 9,232 shares
@ $1.5, valued at
$13.8k
|
|
02/12/2018 |
4
| Shepard Jay (President and CEO) has filed a Form 4 on Versartis, Inc.
Txns:
| Sold 14,446 shares
@ $1.8, valued at
$26k
|
|
12/22/2017 |
4
| Shepard Jay (President and CEO) has filed a Form 4 on Versartis, Inc.
Txns:
| Granted 223,000 shares
@ $0 |
|
10/10/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/15/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
|